Independent prognostic value of KRAS mutation in resected colorectal cancer based on multi-gene sequencing

Table 3 Association between FBXW7 mutation status and clinicopathological features, n (%)

Clinicopathological feature	Total (n = 87)	FBXW7 mutant (n = 24)	FBXW7 wild-type (n = 63)	χ² value	P value
Tumor location				14.20	< 0.001
Left colon	21 (24.14)	4 (16.67)	17 (26.98)
Rectum	46 (52.87)	20 (83.33)	26 (41.27)
Right colon	20 (22.99)	0 (0.00)	20 (31.75)
Differentiation grade				0.01	1.000
Well/moderate	72 (82.76)	20 (83.33)	52 (82.54)
Poor	15 (17.24)	4 (16.67)	11 (17.46)
Lymphovascular invasion				0.88	0.347
Absent	51 (58.62)	16 (66.67)	35 (55.56)
Present	36 (41.38)	8 (33.33)	28 (44.44)
Perineural invasion				0.02	0.895
Absent	75 (86.21)	20 (83.33)	55 (87.30)
Present	12 (13.79)	4 (16.67)	8 (12.70)
Preoperative pathology				0.02	0.901
Adenocarcinoma (non-special)	82 (94.25)	22 (91.67)	60 (95.24)
Mucinous adenocarcinoma	5 (5.75)	2 (8.33)	3 (4.76)
T stage				0.82	0.365
T1 + T2	5 (5.75)	0 (0.00)	5 (7.94)
T3 + T4	82 (94.25)	24 (100.00)	58 (92.06)
N stage				0.02	0.895
N0	12 (13.79)	4 (16.67)	8 (12.70)
N1 + N2	75 (86.21)	20 (83.33)	55 (87.30)
M stage				3.65	0.056
M0	71 (81.61)	16 (66.67)	55 (87.30)
M1	16 (18.39)	8 (33.33)	8 (12.70)
Tumor number				3.82	0.051
Solitary	75 (86.21)	24 (100.00)	51 (80.95)
Multiple (≥ 2)	12 (13.79)	0 (0.00)	12 (19.05)
Maximum tumor diameter				5.77	0.016
< 5 cm	32 (36.78)	4 (16.67)	28 (44.44)
≥ 5 cm	55 (63.22)	20 (83.33)	35 (55.56)
Preoperative tumor markers				2.87	0.090
Normal	65 (74.71)	21 (87.50)	44 (69.84)
Elevated	22 (25.29)	3 (12.50)	19 (30.16)
Microsatellite				1.20	0.274
Microsatellite stable	81 (93.10)	24 (100.00)	57 (90.48)
Microsatellite instability	6 (6.90)	0 (0.00)	6 (9.52)